Entity

Time filter

Source Type


Zhao Y.,Clinical Research and Health Screening | Ho P.,Clinical Research and Health Screening | Yih Y.,Clinical Research and Health Screening | Chen C.,National University of Singapore | And 5 more authors.
Neurobiology of Aging | Year: 2011

Overlapping neurodegenerative pathologies (including Alzheimer's disease, AD) have been described in Parkinson's disease (PD) patients with leucine-rich repeat kinase-2 (LRRK2) mutations. We analyzed a LRRK2 PD (R1628P) risk variant in a group of 885 subjects comprising of AD and controls. The frequency of the R1628P allele was higher in AD compared to controls (3.5% vs. 1.6%, OR 2.3, 95 CI 1.2-4.4, p=0.018). In vitro, the mean percentage of apoptosis and cell death observed for the R1628P transfected human cell lines was higher compared to wild type 21.8 ± 1.9, vs. 17.1 ± 1.3, p<0.05, 30.2 ± 2.2 vs. 25.7 ± 1.3, p<0.05). The LRRK2 R1628P variant increases the risk of AD in our population and our in vitro findings suggest that it is a functional variant and predisposes to apoptosis. © 2009 Elsevier Inc. Source


Tan E.K.,Clinical Research and Health Screening | Tan E.K.,National Neuroscience Institute | Tan E.K.,National University of Singapore | Ho P.,Clinical Research and Health Screening | And 6 more authors.
Neurobiology of Aging | Year: 2011

In a case control study involving 484 study subjects, we showed that the CALHM1 allele (13.5% vs 16.7%) and genotype frequency was not significantly different between Alzheimer's disease (AD) and controls. Logistic regression analysis did not reveal any interaction between ApoE4 allele and CALHM1 allele. © 2009 Elsevier Inc. Source

Discover hidden collaborations